Multiple Sclerosis & Immune Disorders

Filter Your Results

 

News

 

Multiple Sclerosis—The Truth Lies Within Us

Daniel Kantor, MD

November/December 2017—Data presented at the recent ECTRIMS offer fresh insight and potentially new direction into the cause of multiple sclerosis.

ECTRIMS Data Signal Renewed Emphasis on Multiple Sclerosis Disease Progression, Disability

November/December 2017—Data presented at the Seventh Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research in Multipl…

Discontinuing Disease-Modifying Therapy in Multiple Sclerosis: Should You Have an Exit Strategy?

With Robert Naismith, MD and John Corboy, MD

November/December 2017—Two experts sound off on the implications of indefinite treatment and whether DMTs should be stopped.

Forward Thinking: Advances in Neurology

November/December 2017—A review of notable neurological developments in 2017 and a preview of the year ahead.

ECTRIMS: Genentech Data Signals Emphasis on Multiple Sclerosis Disease Progression, Disability

Friday, October 27, 2017—Data presented by Genentech at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research i…

ECTRIMS: Alkermes Demontrates Safety and GI Tolerability of Investigational Oral Agent for Relapsing MS

Friday, October 27, 2017—Alkermes presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a novel, oral monom…

ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

Friday, October 27, 2017—Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the pro…

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Friday, October 27, 2017—Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple scleros…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC